OncoMatch/Clinical Trials/NCT04698564
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
Is NCT04698564 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Hyperpolarized 13C-Pyruvate for prostate cancer.
Treatment: Hyperpolarized 13C-Pyruvate — This is a two-tiered pilot study in which there will be no randomization and no placebo treatment. This study will be to perform metabolic magnetic resonance imaging on men suspected to have a prostate cancer to understand if metabolic MRI can be safely performed on this population
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Maryland Medical Center · Baltimore, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04698564 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 80 years or younger and at least 40 years old.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages